Tokyo, Japan, Jan 22, 2007 - (JCN Newswire) - Eisai Co., Ltd. (TSE: 4523) announced today that on January 16 (U.K. time) the company's UK subsidiary Eisai Ltd. (Headquarters: London, Managing Director: Paul Hooper) received a marketing authorization approval for the anti-epileptic agent Inovelon(R) (rufinamide) indicated as adjunctive therapy in Lennox-Gastaut Syndrome (LGS) from the European Commission (EC).
